2,4-dibromo-6-(((4-bromophenyl)amino)methyl)phenol | 1323851-56-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,4-dibromo-6-(((4-bromophenyl)amino)methyl)phenol
• 英文别名: 2,4-Dibromo-6-[(4-bromoanilino)methyl]phenol
• CAS: 1323851-56-4
• 化学式: C₁₃H₁₀Br₃NO
• 分子量: 435.94
• InChiKey: KDWDCJGSWIWOHN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,4-dibromo-6-(((4-bromophenyl)amino)methyl)phenol 、 异氰酸苯酯 以 氯仿 为溶剂， 以76%的产率得到1-(4-bromophenyl)-1-(3,5-dibromo-2-hydroxybenzyl)-3-phenylurea
  参考文献：
  名称：

  Design, synthesis and biological evaluation of urea derivatives from o-hydroxybenzylamines and phenylisocyanate as potential FabH inhibitors

  摘要：

  FabH, beta-ketoacyl-acyl carrier protein (ACP) synthase III, is a particularly attractive target, since it is central to the initiation of fatty acid biosynthesis and is highly conserved among Gram-positive and Gram-negative bacteria. A series of o-hydroxybenzylamines 1-16 and its corresponding new urea derivatives 17-32 were synthesized and fully characterized by spectroscopic methods and elemental analysis. This new urea derivatives class demonstrates strong antibacterial activity. Escherichia coli FabH inhibitory assay and docking simulation indicated that the compounds 1-(5-bromo-2-hydroxybenzyl)-1-(4-fluorophenyl)-3-phenylurea (18) and 1-(5-bromo-2-hydroxybenzyl)-1-(4-chlorophenyl)-3-phenylurea (20) were potent inhibitors of E. coli FabH. Crown Copyright (C) 2011 Published by Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.06.049
• 作为产物：
  描述：

  3,5-二溴水杨醛 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 生成 2,4-dibromo-6-(((4-bromophenyl)amino)methyl)phenol
  参考文献：
  名称：

  Design, synthesis and biological evaluation of urea derivatives from o-hydroxybenzylamines and phenylisocyanate as potential FabH inhibitors

  摘要：

  FabH, beta-ketoacyl-acyl carrier protein (ACP) synthase III, is a particularly attractive target, since it is central to the initiation of fatty acid biosynthesis and is highly conserved among Gram-positive and Gram-negative bacteria. A series of o-hydroxybenzylamines 1-16 and its corresponding new urea derivatives 17-32 were synthesized and fully characterized by spectroscopic methods and elemental analysis. This new urea derivatives class demonstrates strong antibacterial activity. Escherichia coli FabH inhibitory assay and docking simulation indicated that the compounds 1-(5-bromo-2-hydroxybenzyl)-1-(4-fluorophenyl)-3-phenylurea (18) and 1-(5-bromo-2-hydroxybenzyl)-1-(4-chlorophenyl)-3-phenylurea (20) were potent inhibitors of E. coli FabH. Crown Copyright (C) 2011 Published by Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.06.049

文献信息

• HALOGENATED SALICYLANILIDES FOR TREATING CLOSTRIDIUM INFECTIONS
  申请人：UNION therapeutics A/S

  公开号：EP3302492B1

  公开（公告）日：2021-03-17
• NON-AQUEOUS TOPICAL COMPOSITIONS COMPRISING A HALOGENATED SALICYLANILIDE
  申请人：UNION therapeutics A/S

  公开号：EP3429691B1

  公开（公告）日：2020-11-04
• [EN] NON-AQUEOUS TOPICAL COMPOSITIONS COMPRISING A HALOGENATED SALICYLANILIDE<br/>[FR] COMPOSITIONS TOPIQUES NON AQUEUSES COMPRENANT UN SALICYLANILIDE HALOGÉNÉ
  申请人：ANTIBIOTX APS

  公开号：WO2017157997A1

  公开（公告）日：2017-09-21

  The present invention relates to non-aqueous topical compositions comprising a halogenated salicylanilide and the use of such compositions in the topical treatment or prevention of diseases and infections, particularly conditions caused by Gram-positive bacteria, for example the topical treatment or prevention of skin infections such as acne, atopic dermatitis and impetigo. Also disclosed are methods for preparing the gel composition.
• [EN] DOSAGE REGIMEN OF HALOGENATED SALICYLANILIDES<br/>[FR] SCHÉMA POSOLOGIQUE DE SALICYLANILIDES HALOGÉNÉS
  申请人：ANTIBIOTX AS

  公开号：WO2019038443A1

  公开（公告）日：2019-02-28

  A dosage regimen for the topical prevention or treatment of a skin infection or an inflammatory skin condition in a human subject using a halogenated salicylanilide. The topical dosage regimen provides high concentrations of the halogenated salicylanilide in skin tissue which are retained for a prolonged period without the need for further topical dosing of the halogenated salicylanilide.
• [EN] TREATMENT OF INFECTIONS CAUSED BY NEISSERIA GONOCOCCUS USING A HALOGENATED SALICYLANILIDE<br/>[FR] TRAITEMENT D'INFECTIONS PROVOQUÉES PAR NEISSERIA GONOCOCCUS À L'AIDE D'UN SALICYLANILIDE HALOGÉNÉ
  申请人：UNION THERAPEUTICS AS

  公开号：WO2019192968A1

  公开（公告）日：2019-10-10

  The present invention relates to halogenated salicylanilides, such as closantel, rafoxanide, oxyclozanide, niclosamide, or pharmaceutically acceptable salts or solvates thereof, for use in the treatment of an infection caused by N. gonococcus bacteria in a subject, such as treatment of gonococcal conjunctivitis or anorectal gonorrhoea.